Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study

Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study

BackgroundImmune hyperactivity is an important contributing factor to the morbidity and mortality of COVID-19 infection. Nasal administration of anti-CD3 monoclonal antibody downregulates hyperactive immune responses in animal models of autoimmunity through its immunomodulatory properties. We perfor...

Full description

Bibliographic Details
Main Authors: Thais G. Moreira, Kimble T. F. Matos, Giovana S. De Paula, Thais M. M. Santana, Raquel G. Da Mata, Fernando C. Pansera, Andre S. Cortina, Marcelle G. Spinola, Gerson D. Keppeke, Jules Jacob, Vaseem Palejwala, Karen Chen, Saef Izzy, Brian C. Healey, Rafael M. Rezende, Rogerio A. Dedivitis, Kunwar Shailubhai, Howard L. Weiner
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Immunology
Subjects:
foralumab
anti-CD3
COVID-19
SARS-CoV-2
immune responses
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.709861/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.709861/full

Similar Items